Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1183/09031936.00011814 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pulmonary radioaerosol mucociliary clearance assessment: searching for genotype-specific differences and potential as an outcome measure in primary ciliary dyskinesia.
ERJ Open Res
November 2023
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Background: Pulmonary radioaerosol mucociliary clearance (PRMC) is a reliable method for assessing whole lung mucociliary clearance and has been used at the Danish PCD Centre as a supplementary diagnostic test for primary ciliary dyskinesia (PCD) for more than two decades. This study aimed to investigate genotype-specific differences in PRMC measures and evaluate its potential as an outcome parameter.
Material And Methods: The study was based on a retrospective analysis of PRMC tests performed over a 24-year period (1999-2022) in individuals referred for PCD work-up and included patients with genetically confirmed PCD and non-PCD controls.
Multidrug Aerosol Delivery During Mechanical Ventilation.
J Aerosol Med Pulm Drug Deliv
August 2023
Pulmonary Mechanics and Aerosol Research Laboratory, Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USA.
In the critically ill, pulmonary vasodilators are often provided off label to intubated patients using continuous nebulization. If additional aerosol therapies such as bronchodilators or antibiotics are needed, vasodilator therapy may be interrupted. This study assesses aerosol systems designed for simultaneous delivery of two aerosols using continuous nebulization and bolus injection without interruption or circuit disconnection.
View Article and Find Full Text PDFTechnegas, A Universal Technique for Lung Imaging in Nuclear Medicine: Technology, Physicochemical Properties, and Clinical Applications.
Pharmaceutics
March 2023
Ab Initio Pharma Pty Ltd., 67-73 Missenden Road, Camperdown, NSW 2050, Australia.
Technegas was developed in Australia as an imaging radioaerosol in the late 1980s and is now commercialized by Cyclomedica, Pty Ltd. for diagnosing pulmonary embolism (PE). Technegas is produced by heating technetium-99m in a carbon crucible for a few seconds at high temperatures (2750 °C) to generate technetium-carbon nanoparticles with a gas-like behaviour.
View Article and Find Full Text PDFThe Use of Single Photon Emission Computed Tomography in Aerosol Medicine.
J Aerosol Med Pulm Drug Deliv
February 2023
Department of Medical Physics, University Hospital Southampton NHS Foundation Trust, National Institute of Health Research Biomedical Research Centre, Southampton, United Kingdom.
Imaging of radiolabeled aerosols provides useful data on both the initial site of deposition and its subsequent transport by mucociliary clearance and epithelial permeability. Single Photon Emission Computed Tomography (SPECT) uses a gamma camera with multiple rotating heads to produce three-dimensional (3D) images of inhaled radioaerosol labeled with technetium-99m. This enables total lung deposition and its 3D regional distribution to be quantified.
View Article and Find Full Text PDFVentilation Scintigraphy With Radiolabeled Carbon Nanoparticulate Aerosol (Technegas): State-of-the-Art Review and Diagnostic Applications to Pulmonary Embolism During COVID-19 Pandemic.
Clin Nucl Med
January 2023
Section of Nuclear Medicine, Department of Radiology, Penn State University Hospital, Hershey, PA.
Invented and first approved for clinical use in Australia 36 years ago, Technegas is the technology that enabled ventilation scintigraphy with 99m Tc-labeled carbon nanoparticles ( 99m Tc-CNP). The US Food and Drug Administration (FDA) has considered this technology for more than 30 years but only now is getting close to approving it. Meanwhile, more than 4.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!